Cargando…
FDA perspectives on potential microarray-based clinical diagnostics
The US Food and Drug Administration (FDA) encourages the development of new technologies such as microarrays which may improve and streamline assessments of safety and the effectiveness of medical products for the benefit of public health. The FDA anticipates that these new technologies may offer th...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525154/ https://www.ncbi.nlm.nih.gov/pubmed/16460648 http://dx.doi.org/10.1186/1479-7364-2-4-236 |